IPHA - Innate Pharma SA - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

119.7M

Cash

92.46M

Avg Qtr Burn

-8.14M

Short % of Float

0.24%

Insider Ownership

0.00%

Institutional Own.

0.44%

Qtr Updated

12/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LUMOXITI Details Leukemia, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Monalizumab + durvalumab + oleclumab Details Solid tumor/s, Cancer, Non-small cell lung carcinoma	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IPH6101 / SAR443579 Details Cancer, Relapsed/refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IPH5201 Details Lung cancer, Cancer, Non-small cell lung carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Monalizumab (anti-NKG2A) Details Solid tumor/s, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lacutamab (IPH4102) + GEMOX Details Cancer, Lymphoma, Peripheral T cell cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lacutamab (IPH4102) Details Lymphoma, Cancer, Mycosis fungoides	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lacutamab (IPH4102) Details Lymphoma, Sezary syndrome, Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Avdoralimab (IPH5401) Details COVID-19, Infectious disease	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IPH6401 / SAR’514 Details Cancer, relapsed or refractory light chain amyloidosis, Multiple myeloma, Post-stroke recovery	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IPH6501 Details Cancer, Non-Hodgkin lymphoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lacutamab (IPH4102) Details Cancer, Lymphoma, Peripheral T cell cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IPH5301 (anti-CD73) Details Cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Avdoralimab (IPH5401) Details Bullous pemphigoid , Skin disease/disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Monalizumab (anti-NKG2A) Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.